TrialJournal for immunotherapy of cancer2026

Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.

Rahul Aggarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.